(619) 777-1234

“What many cancer patients don’t know about Taxotere, however, is that the chemotherapy medication has been linked to an increased risk of hair loss (alopecia) that may become permanent, and pending Taxotere lawsuits accuse Sanofi-Aventis of failing to warn the public and healthcare providers about this risk.”

Monroe Law Group – NO FEES UNLESS YOU WIN

Taxotere Case Review

All case evaluations are free and carry no obligation.

You pay nothing until you win your case. Monroe Law Group pays for all costs of the lawsuit up front, and if don’t win, you pay nothing! If we win, you pay a percentage of the awarded settlement.

Taxotere Lawsuits

Are you still bald after chemo? Are you hiding under a baseball cap long after your hair was supposed to grow back? Are your doctors perplexed? If so, you may be one of a growing number of people around the world who have experienced persistent chemo-induced alopecia, or hair loss.

According to Sanofi-Aventis, manufacturer of the chemotherapy drug Taxotere—used to treat breast, lung, gastric, head and neck and prostate cancer—3% of patients administered the drug could experience long-term alopecia. This figure could rise to as high as 6.3% when given in combination with the drugs Adriamycin (doxorubicin) and Cyclophosphamide, according to a study by the Rocky Mountain Cancer Centers in Colorado.

“Such an emotionally devastating long-term toxicity from this combination must be taken into account when deciding on adjuvant chemotherapy programs in women who likely will be cured of their breast cancer,” the study concludes.

Despite this recommendation, patients are not being informed of this potentially disfiguring side effect.

Taxotere and Permanent Hair Loss, Sanofi-Aventis, the company that makes Taxotere, has been accused of failing to warn about the risk of permanent hair loss until December 2015, when the FDA updated the label.

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm212079.htm

Studies connecting Taxotere to permanent or persistent hair loss has been on the rise for years. A 2006 study by Dr. Scot Sedlacek found that 6.3% of breast cancer patients grew back less than 50% of their hair after using Taxotere when combined with Adriamycin (docorubicin) and Cytoxan (cyclophosphamide).

How Can the Monroe Law Group Help?

The Monroe Law Group is accepting Taxotere permanent and persistent hair loss cases in all 50 states. If you or loved one has been diagnosed with persistent or permanent hair loss, you should contact our expert attorneys immediately for a free, confidential case consultation. Please call 888-879-7106 or email us at intake@monroelawgroup.com to speak to one of our attorneys, or complete the free case evaluation on this page. Our cases are always free unless there is a settlement or verdict in your favor.

Taxotere Side Effects

A growing number of studies have shown that side effects of the chemotherapy drug Taxotere (docetaxel) may result in an increased risk of persistent or permanent hair loss in cancer patients taking the medication. In fact, one report conducted by the National Cancer Research Institute in November 2014 indicated that 10-15% of patients taking Taxotere, also known as docetaxel or docefrez, may experience permanent baldness as a side effect of the chemotherapy treatment. If you believe you have been adversely affected by hair loss side effects of Taxotere, contact a knowledgeable Taxotere attorney today to discuss your legal options. You may have grounds to file a product liability lawsuit against Taxotere maker Sanofi-Aventis, in order to seek fair and timely reimbursement for your losses.

Studies Linking Taxotere to Side Effects

Permanent chemotherapy-induced alopecia: case report and review of the literature.

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

Links to Taxotere Support Groups

Taxotears

A Head of Our Time

Did you take Taxotere, Docetaxel or Docefrez as a form of chemotherapy to treat cancer?

Taxotere is a chemotherapy medication belonging to a group of drugs called taxanes, which are designed to prevent harmful cancer cells from growing and dividing. Taxotere is currently manufactured by pharmaceutical company Sanofi-Aventis, and is commonly prescribed for the treatment of breast cancer, metastatic prostate cancer, non-small cell lung cancer, and head and neck cancer. What many cancer patients don’t know about Taxotere, however, is that the chemotherapy medication has been linked to an increased risk of hair loss (alopecia) that may become permanent, and pending Taxotere lawsuits accuse Sanofi-Aventis of failing to warn the public and healthcare providers about this risk.

When did you start taking the chemotherapy drug?

Originally approved by the U.S. Food and Drug Administration (FDA) in 2006, Taxotere has been used by millions of Americans diagnosed with breast cancer and other types of cancer over the years. The chemotherapy drug is typically administered intravenously in a hospital once every three weeks, sometimes in combination with other medications, and studies have shown that because Taxotere is designed to destroy all rapidly-growing cells, including both cancer cells and healthy cells, it may permanently destroy hair follicles, which are among the fastest-growing cells in the body. In December 2015, the FDA required that changes be made to the Taxotere drug label to include information about the potential for the chemotherapy medication to cause permanent hair loss in users.

Did you suffer permanent hair loss as a result of taking this medication?

There are about 2.8 million women in the United States with a history of breast cancer, and approximately 75% of these women have been prescribed the chemotherapy drug Taxotere, docetaxel or docefrez during the course of their cancer treatment. Although Sanofi-Aventis indicated in Taxotere’s prescribing information that “once you have completed all your treatments, hair generally grows back,” a growing body of research has indicated that baldness from Taxotere treatment may actually become permanent. In fact, while research conducted by Sanofi-Aventis estimates that the risk of permanent hair loss may occur in about 3% of patients, other studies suggest that the risk may be closer to 6%, or even as high as 10-15%.

Do you have a lawyer representing you in this matter?

The Monroe Law Group is accepting Taxotere permanent and persistent hair loss cases in all 50 states. If you or loved one has been diagnosed with persistent or permanent hair loss, you should contact our expert attorneys immediately for a free, confidential case consultation. Please call 888-879-7106 right now to speak to one of our attorneys or complete the free case evaluation on this page. Our cases are always free unless there is a settlement or verdict in your favor.

For cancer patients undergoing chemotherapy treatment with Taxotere, experiencing hair loss (alopecia) that persists long after the treatment is suspended can have devastating psychological side effects, including lowered self-esteem and diminished quality of life. If you took Taxotere for breast cancer or another type of cancer, and you have suffered persistent or permanent baldness as a result, it’s important that you have a qualified product liability lawyer on your side should you choose to pursue a legal claim against Sanofi-Aventis. With the help of an attorney who has experience handling Taxotere hair loss claims, you can ensure that your legal rights are protected, and pursue the financial compensation you deserve for your injuries and medical expenses.

There is no risk to you in consulting one of our lawyers today. Contact Monroe Law Group now by phone at 888-879-7106 or by email at intake@monroelawgroup.com to arrange for your free, no-obligation consultation.

CALL US NOW Free Online Case Review